<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746315</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20004-Ib</org_study_id>
    <nct_id>NCT02746315</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Single-centre, Placebo-controlled, Dose Escalation, Multiple s.c. DoseStudy to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in China. The aim of this trial is to assess the safety and
      tolerability for Multiple s.c injection of HS-20004 in healthy Chinese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 0 and up to 3 days after last treatment (Day 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma HS-20004 concentration curve after the last s.c injection</measure>
    <time_frame>Time 0 to 72 hours after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) after the last dose</measure>
    <time_frame>Time 0 to 72 hours after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (tÂ½) for HS-20004 after the last dose</measure>
    <time_frame>Time 0 to 72 hours after the last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour profiles of plasma glucose and serum insulin from baseline</measure>
    <time_frame>From time 0 to 24 hours after the first and last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-20004</intervention_name>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_label>Experimental 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_label>Experimental 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 19 and 28 kg/m^2, inclusive, and a total body weight of
             at least 50 kg;

        Exclusion Criteria:

          -  Clinically relevant abnormalities of physical examination, laboratory values, vital
             signs or ECG findings at the screening, as judged by the Investigator;

          -  Have any other medical abnormality (such as cardiovascular, hepatic, renal,
             gastrointestinal, immunologic, hematological, hormonal, metabolic, neoplasmatic or
             mental disease), which in the opinion of the investigator, might affect the
             absorption, distribution, metabolism, and excretion of the study drug, or prevent the
             patient from following and completing the protocol;

          -  Family history of diabetes, thyroid cancer, submandibular gland cancer, or history of
             pancreatitis, cholelithiasis, drug allergy, serious unconscious hypoglycemia or
             positive of anxious chronic viral hepatitis B, HIV antibody;

          -  History of drug or alcohol abuse within 6 months before randomization;

          -  Use of GLP-1 analogues, DPP-IV enzyme inhibitors, as well as other hypoglycemic drugs
             within 3 months before randomization;

          -  Use of any prescription drugs and Chinese herbal medicines within 4 weeks before
             randomization;

          -  Use of non prescription drugs and food supplements (vitamins, etc.) within 2 weeks
             before randomization;

          -  Participated any drug clinical trials within 3 months, or participated 3 or more than
             3 drug clinical trials within 1 year, or had blood donation/loss &gt;400mL within 3
             months before randomization;

          -  Female subject of childbearing potential who does not use an acceptable method of
             birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject
             who does not use an acceptable method of birth control, within six months before
             randomization;

          -  Subject who cannot refrain from smoking, eating and/or drinking containing
             xanthine/caffeine, or strenuous exercise, or others that affect drug absorption,
             distribution, metabolism and excretion within 2 days before the study drug
             administration; Subject who is unsuitable for inclusion in the study in the opinion of
             the investigator;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

